Merck (NYSE: MRK) surpassed analysts’ expectations for revenue and earnings in the third quarter of 2019, sending the shares climbing 2.5% in premarket hours on Tuesday.
Worldwide sales rose 15% year-over-year to $12.4 billion, beating estimates of $11.6 billion. Excluding foreign exchange impacts, sales grew 16%. Sales growth was driven by strength in oncology and human health vaccines.
On a GAAP basis, net income fell 3% to $1.9 billion while EPS rose 1% to $0.74. Adjusted net income grew 22% to $3.8 billion. Adjusted EPS increased 27% to $1.51, topping forecasts of $1.24.
Pharmaceutical sales increased 15% year-over-year to $11.1 billion, driven by oncology and vaccines. During the quarter, KEYTRUDA sales grew 62% to $3.1 billion and human health vaccines increased 17% to $2.5 billion. Pharma sales were negatively impacted by the loss of market exclusivity for some products as well as lower sales in JANUVIA and JANUMET.
Animal Health sales grew 10% to $1.1 billion, mainly driven by livestock as well as growth in companion animal products.
R&D expenses, on a GAAP basis, increased 55% to $3.2 billion versus the prior-year period, driven mainly by a $982 million charge related to the Peloton acquisition and higher clinical development expenses.
For the full year of 2019, Merck narrowed and raised its revenue guidance to a range of $46.5 billion to $47 billion. This compares to the previous range of $45.2 billion to $46.2 billion. The company narrowed and reduced its GAAP EPS outlook to a range of $3.75-3.80, versus the prior outlook of $3.78-3.88. Merck narrowed and raised its adjusted EPS guidance to a range of $5.12-5.17, which compares to the previous range of $4.84-4.94.
Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a
PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the
With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,